246 related articles for article (PubMed ID: 31961625)
1. Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis.
Qin Z; Yao J; Xu L; Xu Z; Ge Y; Zhou L; Zhao F; Jia R
Int Braz J Urol; 2020; 46(5):691-704. PubMed ID: 31961625
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer.
Hu B; Yang H; Yang H
Tumour Biol; 2014 Sep; 35(9):8573-80. PubMed ID: 24863945
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.
Cui Y; Cao W; Li Q; Shen H; Liu C; Deng J; Xu J; Shao Q
Sci Rep; 2016 May; 6():25776. PubMed ID: 27161545
[TBL] [Abstract][Full Text] [Related]
4. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
[TBL] [Abstract][Full Text] [Related]
5. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis.
Luo Y; Gou X; Huang P; Mou C
Asian J Androl; 2014; 16(3):487-92. PubMed ID: 24713827
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis.
Luo Y; Gou X; Huang P; Mou C
Chin Med J (Engl); 2014; 127(9):1768-74. PubMed ID: 24791889
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer.
Mao Z; Ji A; Yang K; He W; Hu Y; Zhang Q; Zhang D; Xie L
Medicine (Baltimore); 2018 Oct; 97(42):e12806. PubMed ID: 30334974
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis.
Lee D; Shim SR; Ahn ST; Oh MM; Moon DG; Park HS; Cheon J; Kim JW
Clin Genitourin Cancer; 2020 Oct; 18(5):402-408.e5. PubMed ID: 32280028
[TBL] [Abstract][Full Text] [Related]
9. Comparison of diagnostic efficacy by two urine PCA3 scores in prostate cancer patients undergoing repeat biopsies.
Jiang Z; Zhao Y; Tian Y
Minerva Urol Nefrol; 2019 Aug; 71(4):373-380. PubMed ID: 30203935
[TBL] [Abstract][Full Text] [Related]
10. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer antigen 3 as a biomarker in the urine for prostate cancer diagnosis: a meta-analysis.
Xue WJ; Ying XL; Jiang JH; Xu YH
J Cancer Res Ther; 2014 Nov; 10 Suppl():C218-21. PubMed ID: 25450286
[TBL] [Abstract][Full Text] [Related]
12. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
13. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
14. The potential diagnostic accuracy of circulating microRNAs for prostate cancer: A meta-analysis.
Zhang WT; Zhang GX; Zhao RZ; Gao SS
Actas Urol Esp (Engl Ed); 2022 Apr; 46(3):138-149. PubMed ID: 35260368
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
16. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
17. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis].
Ruiz-Aragón J; Márquez-Peláez S
Actas Urol Esp; 2010 Apr; 34(4):346-55. PubMed ID: 20470697
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA as a potential diagnostic tool for prostate cancer: a systematic review and meta-analysis.
Li Y; Wei C; Huang C; Ling Q; Zhang L; Huang S; Liao N; Liang W; Cheng J; Wang F; Mo L; Mo Z; Li L
Biomarkers; 2023 Feb; 28(1):1-10. PubMed ID: 36323640
[TBL] [Abstract][Full Text] [Related]
20. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
